|
|
|
|
|
|
|
|
|
|
New Data Demonstrates Effectiveness of Clarient’s Ovatax™ Test for Ovarian Cancer.
See study, titled “Expression of TLE3 Predicts Response to Taxane Therapy in Ovarian Carcinoma,” included 293 carcinoma samples mostly collected at UAB
Monday, August 09, 2010
Ovatax
New Data Demonstrates Effectiveness of Clarient’s Ovatax™ Test for Ovarian Cancer.
See study, titled “Expression of TLE3 Predicts Response to Taxane Therapy in Ovarian Carcinoma,” included 293 carcinoma samples mostly collected at UAB
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.